Every 8-K that SAB Biotherapeutics, Inc. (SABS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SABS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SABS filings page.
SAB Biotherapeutics, Inc. filed a current report describing a new grant-funded clinical study of its lead candidate SAB-142 in type 1 diabetes. Breakthrough T1D has awarded a grant to support the PRISE‑hATG trial, led by Dr. Michael J. Haller at the University of Florida.
The PRISE‑hATG study will evaluate SAB‑142 in patients with Stage 3 type 1 diabetes who are between 100 days and two years from diagnosis, a group that typically falls outside earlier-stage trials. SAB BIO will co-fund the trial, which is designed to assess whether SAB‑142 can preserve C‑peptide and modulate immune responses. The study complements SAB BIO’s ongoing Phase 2b SAFEGUARD trial of SAB‑142 in newly diagnosed Stage 3 patients.
SAB Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026. A total of 59,349,534 shares were present in person or by proxy out of 77,966,409 shares entitled to vote, representing approximately 76.12% of the outstanding common stock and establishing a quorum.
Shareholders elected four Class II directors for three-year terms: David Zaccardelli, Pharm.D., David Link, MBA, Katie Ellias, and Andrew Moin. Each received over 44 million votes in favor, with broker non-votes of 10,994,436 reported for each nominee.
Stockholders also ratified EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 59,319,363 votes for, 3,373 against, and 26,798 abstentions.
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for clinical and commercial production of its SAB-142 product at Emergent’s Canadian facility. The agreement becomes a long-term framework once SAB-142 receives U.S. FDA approval.
After any FDA approval, the agreement runs for five years and includes a minimum aggregate spend of $36 million over that post-approval term. Emergent has the exclusive right to manufacture SAB-142 during the term, while SAB Biotherapeutics may use alternative sources only when Emergent cannot or declines to supply.
The agreement includes multiple termination rights, including for insolvency, non-payment, material breach, mutual agreement, or extended force majeure. If Emergent terminates due to SAB Biotherapeutics’ insolvency, non-payment, or material breach, SAB Biotherapeutics must pay Emergent an amount equal to the minimum annual aggregate spend for each remaining calendar year, less saved costs.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 common shares at $3.85 per share and pre-funded warrants to purchase up to 2,753,246 shares at $3.8499 per warrant. Gross proceeds are expected to be about $85 million, with estimated net proceeds of roughly $69.7 million, or $81.7 million if underwriters fully exercise a 30-day option for up to 3,311,688 additional shares. The company plans to use the cash, together with existing funds, primarily to advance its lead T1D candidate SAB-142 through ongoing and planned clinical trials, as well as related manufacturing, regulatory and general corporate needs.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics, Inc. reported that on January 12, 2026 it posted an updated corporate presentation on its official website. The presentation, dated January 12, 2026 and referenced as Exhibit 99.1, is intended for investors and other stakeholders seeking an overview of the company and its plans. The disclosure notes that this presentation is being furnished rather than filed under securities laws, meaning it is not automatically incorporated into other regulatory documents unless specifically referenced.
SAB Biotherapeutics, Inc. reported that its board appointed David Zaccardelli, Pharm.D., and Rita Jain, M.D., as Class II directors effective January 5, 2026. They will serve until the 2026 annual meeting of stockholders or until successors are elected and qualified.
Dr. Zaccardelli has been named Chairperson of the Board, while Chief Executive Officer Samuel J. Reich steps down as chair but continues as a director. Both new directors were recommended by RA Capital Healthcare Fund, L.P. under a July 21, 2025 letter agreement related to a July 2025 private placement. They will receive compensation similar to other non-employee directors and have entered into customary indemnity agreements. On January 7, 2026, the company issued a press release announcing these appointments.
SAB Biotherapeutics, Inc. reported that on September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from its Board of Directors. Their departures were made in line with a letter agreement between the company and RA Capital Healthcare Fund, L.P. related to a July 2025 private placement of securities. Following these resignations, the Board size was reduced from 11 to nine members. The company stated that the resignations were not due to any disagreement regarding its operations, policies, or practices and expressed appreciation for both directors’ service.
SAB Biotherapeutics, Inc. stockholders approved two major equity-related proposals at a special meeting. First, they approved the potential issuance of more than 19.99% of the company’s outstanding common stock upon conversion of its Series B Convertible Preferred Stock at less than the Nasdaq “minimum price,” a step that may be deemed a change of control under Nasdaq rules.
Second, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan that increases the share pool for awards by 24,180,000 shares to an aggregate of 31,932,466 shares and raises the maximum annual “evergreen” increase from 10,000,000 shares to 73,750,000 shares. The Plan amendment passed with 5,089,862 votes for and 951,598 against, while the Series B conversion proposal passed with 5,502,026 votes for and 515,275 against.